Children's Mercy Hospital Collaborative Fellowship Program in Pediatric Pharmacology

儿童慈善医院儿科药理学合作奖学金计划

• 批准号: 9270585
• 负责人: SUSAN M ABDEL-RAHMAN
• 金额: $ 12.93万
• 依托单位: CHILDREN'S MERCY HOSP (KANSAS CITY, MO)
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2021-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9270585
• 关键词: Child; Fellowship Program; Hospitals; pediatric pharmacology

 DESCRIPTION (provided by applicant): The Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation at Children's Mercy Hospital (CMH) in Kansas City, offers one of the largest, most diverse, Pediatric Clinical Pharmacology post-doctoral training programs in the U.S. It is constituted by 20 faculty including 1) clinicians cross-trained in Allergy/Asthma/Immunology, Behavioral Medicine, Cardiology, Gastroenterology, Hematology/Oncology, Infectious Diseases, Maternal/Fetal Medicine, Neonatology, Nephrology, Pharmacy, Rehabilitation Medicine, Rheumatology, and Toxicology, along with 2) basic/translational scientists with experience in analytical chemistry, applied mathematics, genetics, genomics, in vitro biotransformation, and molecular biology. Affiliated faculty contribute additional expertise in the areas of Bioethics, Health Outcomes, Pharmacoepidemiology, and Psychosocial Research. The program has made substantial contributions in the areas of pharmacogenetics, developmental pharmacokinetics, and early phase clinical trial design. The program defined in this application combines robust didactic and experiential training in pharmacogenetics/genomics, metabolomics, pharmacometrics, pharmacoepidemiology, drug discovery, drug development, clinical trial design, and the responsible conduct of research. It also offers unique elective opportunities dedicated to pediatric PBPK-based modeling and simulation (Simcyp/Certara), pediatric regulatory review and approval (FDA), bioinformatics (PharmGKB), and Formulary management (CMH/Medicaid). Two independent Masters programs offered by affiliated medical schools round out the academic program at CMH. All teaching is accomplished by faculty with significant research experience in their respective subject areas. Trainees affiliate with the program for a minimum of three years; the first and second years in Clinical Pharmacology are blended with the second (PGY5) and third (PGY6) years of their subspecialty training and their third year (PGY7) is dedicated to clinical pharmacology. Under the direction of both a junior and senior mentor, fellows will complete both a clinical and translational research project, produce several publications/presentations, compete for a minimum of one research grant, and develop a plan to transition to independence prior to graduation. Quality is continually assured by a robust, multi- input, evaluation strategy and diversity is supported by a comprehensive recruitment strategy. Since its inception, the training program at CMH has graduated 17 pediatric clinical pharmacology fellows (14 pediatricians, 3 clinical pharmacists; 11 female, 2 African American, 1 Hispanic, 1 Native-American, 1 Asian descent) who have collectively delivered 71 scientific presentations, prepared 77 peer-reviewed manuscripts and successfully competed for over $1,000,000 in intramural and extramural funding. The program is one of only two American Board of Clinical Pharmacology accredited training programs dedicated to Pediatric Clinical Pharmacology. Its longstanding record of excellence provides applicants with unparalleled training in Pediatric Clinical Pharmacology.

 描述（申请人提供）：堪萨斯城儿童慈善医院（CMH）的临床药理学、毒理学和治疗创新部提供美国最大、最多样化的儿科临床药理学博士后培训项目之一。血液学/肿瘤学、传染病学、孕产妇/胎儿医学、新生儿科、肾脏病学、药学、康复医学、风湿病学和毒理学，以及2）具有分析化学、应用数学、遗传学、基因组学、体外生物转化和分子生物学经验的基础/转化科学家，沿着。附属教师在生物伦理学，健康结果，药物流行病学和心理社会研究领域提供额外的专业知识。该项目在药物遗传学、发育药代动力学和早期临床试验设计领域做出了重大贡献。在此应用程序中定义的程序结合了强大的教学和经验的药物遗传学/基因组学，代谢组学，药物计量学，药物流行病学，药物发现，药物开发，临床试验设计和负责任的研究行为的培训。它还提供独特的选修机会，致力于儿科基于PBPK的建模和模拟（Simcyp/Certara），儿科监管审查和批准（FDA），生物信息学（PharmGKB）和处方集管理（CMH/Medicaid）。由附属医学院提供的两个独立的硕士课程完善了CMH的学术课程。所有的教学都是由在各自学科领域具有丰富研究经验的教师完成的。受训人员参加该计划至少三年;临床药理学的第一年和第二年与第二年（PGY 5）和第三年（PGY 6）的亚专业培训相结合，第三年（PGY 7）致力于临床药理学。在初级和高级导师的指导下，研究员将完成临床和转化研究项目，制作几个出版物/演示文稿，竞争至少一个研究资助，并制定计划在毕业前过渡到独立。质量不断得到强有力的多投入评价战略的保证，多样性得到全面招聘战略的支持。自成立以来，CMH的培训计划已毕业17名儿科临床药理学研究员（儿科医师14名，临床药师3名; 11名女性，2名非洲裔美国人，1名西班牙裔美国人，1名美国原住民，1名亚洲血统），他们共同发表了71份科学报告，编写了77份同行评审的手稿，并成功竞争了1000多美元，1000美元的校内和校外资助。该计划是仅有的两个美国临床药理学委员会认可的专门用于儿科临床药理学的培训计划之一。其长期以来的卓越记录为申请人提供了儿科临床药理学方面无与伦比的培训。